A new drug to treat psoriasis has been developed and is in clinical testing. Assume that those individuals given the drug are examined before receiving the treatment and then again after receiving the treatment to determine if there was a change in their symptom status. If the initial results showed that 2.0% of individuals entered the study in remission, 77.0% of individuals entered the study with mild symptoms, 16.0% of individuals entered the study with moderate symptoms, and 5.0% entered the study with severe symptoms calculated and interpret a chi-squared test to determine if the drug was effectively treating psoriasis given the information below from the final examination.

	Remission (No Symptoms of Psoriasis)	Mild Symptoms of Psoriasis	Moderate Symptoms of Psoriasis	Severe Symptoms of Psoriasis	Total Number of Participants to Receive the Drug
Number of Participants	380	520	95	5

 

Transcribed Image Text:

A) We reject HO because 6628.08 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. B) We reject HO because 6628.08 is greater than 9.49. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. C) We reject HO because 6628.08 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. D) We reject HO because 6628.08 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. A) We reject HO because 6628.08 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. B) We reject HO because 6628.08 is greater than 9.49. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. C) We reject HO because 6628.08 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. D) We reject HO because 6628.08 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.